Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 74, Issue 10, 2013, Pages 966-973

  Smith, Eric G ^a   Deligiannidis, Kristina M ^b   Ulbricht, Christine M ^b   Landolin, Chelsea S ^b   Patel, Jayendra K ^b   Rothschild, Anthony J ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Bonita House Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MEMANTINE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAROXETINE; PLACEBO; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84887043337     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08252     Document Type: Article

References (29)

1. Zarate CA J.r., Singh JB, Carlson P.J., et al A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. (Pubitemid 44188478)
2. Berman RM, Cappiello A, Anand A., et al Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. (Pubitemid 30109248)
3. Machado-Vieira R., Ibrahim L, Henter I.D., et al Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav. 2012;100(4):678-687.
4. Mathew SJ, Murrough J W, Aan Het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Ne uropsychophar macol. 2010;13(1):71-82.
5. Sanacora G, Zarate CA, Krystal J.H., et al Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437. (Pubitemid 351619114)
6. Zarate CA J.r., Singh JB, Quiroz J.A., et al A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-155. (Pubitemid 43050119)
7. Rogóz Z., Skuza G, Kuśmider M, et al Synergistic effect of imipramine and amantadine in the forced swimming test in rats: behavioral and pharmacokinetic studies. Pol J Phar macol. 2004;56(2):179-185 (Pubitemid 38931384)
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389 (Pubitemid 9136500)
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
10. Sheehan DV, Lecrubier Y, Sheehan K.H., et al The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. (Pubitemid 29001829)
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
12. Williams JB, Kobak KA, Bech P, et al The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3): 120-129 (Pubitemid 351535903)
13. Oquendo MA, Baca-Garcia E, Kartachov A., et al A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003;64(7):825-833 (Pubitemid 36897220)
14. Folstein MF, Folstein SE, McHugh PR "Mini-mental state,": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198
15. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343-352 (Pubitemid 9157284)
16. Rush AJ, Trivedi MH, Ibrahim H.M., et al The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583 (Pubitemid 37289444)
17. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
18. Spitzer R, Endicott J. Schedule for Affective Disorders and Schizophrenia. 3rd ed. New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 1979.
19. Feingold A. Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods. 2009;14(1):43-53.
20. Vickers AJ. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BMC Med Res Methodol. 2003;3(1):22.
21. Paul SM, Mytelka DS, Dunwiddie C.T., et al How to improve R & D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
22. Anand A, Gunn AD, Barkay G, et al Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012;14(1):64-70.
23. Muhonen LH, Lönnqvist J, Juva K., et al Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392-399. (Pubitemid 351549391)
24. Ferguson JM, Shingleton RN An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007; 30(3):136-144. (Pubitemid 46871863)
25. Green SM, Coté CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med. 2009;54(2):181-190.
26. Department of Health and Human Services. Anesthetic and Life Support Drugs Advisory Committee Meeting. March 29, 2007. Accessed April 12, 2013. http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4285t1.pdf.
27. FDA Advisory Committee Background Document to the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC). March 10, 2011. Accessed April 12, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ UCM245769.pdf.
28. Lieberman JA, Papadakis K, Csernansky J., et al.; MEM-MD-29 Study Group. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009;34(5):1322-1329
29. Lenze EJ, Skidmore ER, Begley A.E., et al Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry. 2012;27(9):974-980.